The Mesothelioma Applied Research Foundation is proud to announce the recipients of its most recent round of new mesothelioma research funding. Through a rigorous review…
This week, the paper “Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations,” by Drs. Michele Carbone, Harvey Pass, and…
Data from a study comparing the efficacy of anetumab ravtansine, a monoclonal antibody conjugate, against vinorelbine showed no improvement in progression-free survival. The results of…
“We are at a point where in the next few years we’re going to have a lot more options for our patients,” said Dr. Hedy…
The field of radiology and imaging has relatively quickly advanced from simple x-rays that allow us to take a non-invasive, albeit limited, peek inside the…
As 2021 concludes and 2022 begins, we bring you mesothelioma treatment news directly from clinicians and researchers. Two newly published articles give us a useful…
This week, Nature Medicine published the results, as well the genomic and immunologic analyses, from the Phase 2 PrE0505 clinical trial. The trial, which took…
Jessica Blackford-Cleeton and Rich Mosca, both members of the mesothelioma community, recently participated in the evaluation of research proposals for funding through the Congressionally Directed…
Today, Bristol Myers Squibb announced new three-year overall survival data from its CheckMate -743 study. These data are based on the clinical trial of nivolumab/ipilimumab…
Today, the Mesothelioma Applied Research Foundation announced the selection and funding of three new research awards for mesothelioma research. The three grants, each at $100,000,…